Due to the position of ERKs at the end of the pathway and their low mutation rate, the development of ERK inhibitors has attracted widespread attention from researchers, and has already entered multiple clinical trials.9–11 However, due to adverse effects and unsatisfactory efficacy, none of the ERK1/2 inhibitors has been approved for cancer treatment to date. This evidence concerns the gene MAPK3 and cancer.